Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection Trials Aim to Show Superiority of Ridinilazole Over Standard of Care Treatment Vancomycin Health Economic Outcomes Included to Support Commercialisation Oxford, UK, and Cambridge, MA, US, 13 February 2019 – Summit...
Author: @admin
Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection Trials Aim to Show Superiority of Ridinilazole Over Standard of Care Treatment Vancomycin Health Economic Outcomes Included to Support Commercialisation Oxford, UK, and Cambridge, MA, US, 13 February 2019 – Summit...
FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
Cryptococcal Meningitis Included in FDA Tropical Disease Priority Review Voucher Program SAN DIEGO – February 11, 2019 – Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Product Development has granted orphan drug designation to APX001, the company’s lead drug candidate,...
Summit Therapeutics to Present at the BIO CEO & Investor Conference
Summit Therapeutics plc (‘Summit’ or the ’Company’) READ FULL TEXT
Summit Therapeutics to Present at the BIO CEO & Investor Conference
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Therapeutics to Present at the BIO CEO & Investor Conference Oxford, UK, and Cambridge, MA, US, 8 February 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces that Mr Glyn Edwards, Chief Executive Officer, will present at the BIO...
New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek’s NUZYRA™ (Omadacycline) For Pneumonia and Skin Infections
Once-daily IV-to-oral NUZYRA safe and effective in adults with pneumonia and skin infections, demonstrating clinical activity against relevant pneumonia- and skin-associated drug resistant bacteria BOSTON, Feb. 06, 2019 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced The New...
VenatoRx Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference
Malvern, PA, February 6, 2019 – VenatoRx Pharmaceuticals, a world leader in antibacterial and antiviral drug research and development, announced that its Chief Business Officer, Tony Meehan, MBA, PhD, will present at the 2019 BIO CEO & Investor Conference. Presentation Details: Date: Monday, February 11, 2019 Time: 3:30pm ET Location: New York Marriott Marquis (Gramercy...
Paratek Pharmaceuticals Launches NUZYRA™ (Omadacycline) in the United States
— Three Antimicrobial Susceptibility Tests Cleared by FDA for Use with NUZYRA — — Launches KEYSTONETM Surveillance Program to Monitor Omadacycline Susceptibility — BOSTON, Feb. 05, 2019 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced the commercial...
Melinta Therapeutics Provides Corporate Updates
~ Highlights Continued Positive Sales Momentum and Estimated Year-End Cash Position ~ ~ Confirms Previously Announced Cost Savings Guidance ~ ~ Continues Senior Leadership Team Evolution with New Management Appointments ~ NEW HAVEN, Conn., Feb. 04, 2019 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, Feb. 01, 2019 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that on January 31, 2019, the Company granted stock options and restricted stock units to two new employees of the Company. These awards were granted pursuant to the Paratek...